Stocks Health care RXST
NASDAQ · Health careRxSight, Inc. (RXST)
RxSight, Inc. brought in $127.6M of revenue over the twelve months to June 30, 2026, down 13.2% from a year earlier. It posted a net loss of $46.9M. In fiscal 2025 capital spending exceeded operating cash flow by $19.3M. At June 30, 2026 it held $13.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What RxSight, Inc. does
RxSight, Inc. is registered with the SEC under industry code SIC 3851 (Ophthalmic Goods). Its shares trade on NASDAQ under the ticker RXST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $134.5M | -$38.9M | -$0.95 | -$19.3M |
| 2024 | $139.9M | -$27.5M | -$0.71 | -$22.4M |
| 2023 | $89.1M | -$48.6M | -$1.41 | -$46.4M |
| 2022 | $49M | -$66.8M | -$2.41 | -$61.2M |
| 2021 | $22.6M | -$48.7M | -$3.57 | -$46.6M |
| 2021 | $14.7M | $27.6M | $0.15 | -$37.7M |
Where RXST ranks in Health care
Latest SEC filings
What RxSight, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026Form SC TO-I/A filing SC TO-I/A
- August 25, 2026Form SC TO-I/A filing SC TO-I/A
- August 19, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026Form SC TO-I filing SC TO-I
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- August 4, 2026Passive stake changed SCHEDULE 13G/A
- July 23, 2026
- July 17, 2026Passive stake (5% or more) SCHEDULE 13G
- July 15, 2026
Insider trades
What the people running RxSight, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $118K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Weinberg EricSee remarks | Exercised options | 35,168 | $152.6K |
| September 2, 2026 | Weinberg EricSee remarks | Sold | 2,041 | $14.2K |
| September 2, 2026 | Goldshleger IlyaChief Operating Officer | Sold | 2,041 | $14.2K |
| September 2, 2026 | Wilterding MarkChief Financial Officer | Sold | 7,765 | $54K |
| September 2, 2026 | Kurtz Ronald M MDChief Medical Officer | Sold | 5,100 | $35.5K |
| August 31, 2026 | Weinberg EricSee remarks | Exercised options | 5,370 | - |
| August 31, 2026 | Goldshleger IlyaChief Operating Officer | Exercised options | 5,370 | - |
| August 31, 2026 | Wilterding MarkChief Financial Officer | Exercised options | 20,441 | - |
| August 31, 2026 | Kurtz Ronald M MDChief Medical Officer | Exercised options | 13,425 | - |
Questions about RXST
What does RxSight, Inc. do?
RxSight, Inc. is registered with the SEC under industry code SIC 3851 (Ophthalmic Goods). Its shares trade on NASDAQ under the ticker RXST.
Is RxSight, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $46.9M on revenue of $127.6M.
How much revenue does RxSight, Inc. make?
Over the twelve months to June 30, 2026 RxSight, Inc. reported revenue of $127.6M. That is 13.2% less than a year earlier.
When did RxSight, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 16, 2026.
Similar companies
Compare RXST with
Follow RXST
Get an email when RxSight, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow RXST: get an email when it filesWhere the numbers come from
Financial figures are the values RxSight, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.